In malignancy-associated pain, improvement or marked improvement occurred in 5/13 calcitonin recipients versus 0/12 placebo recipients at one week (P = 0.0484).
In plain wordsIn cancer pain, improvement occurred more often with salmon calcitonin than placebo at one week.
- Peptide
- Calcitonin-salmon
- Outcome
- IncreasePain response at one week
- Study
n = 25
- Comparator
- Matching placebo
- Outcome group
- Pain · Nervous system and cognition
- Studied dose
- 200 UI 6-hourly · subcutaneous · 48 hAs given in this study (human).
Measurements
- Pain responders
- 5 patients
- calcitonin
- Evaluated patients
- 13 patients
- calcitonin
- Pain responders
- 0 patients
- placebo
- Evaluated patients
- 12 patients
- placebo
- P
- 0.0484
- Fisher exact two-tailed test
Source sentences
One week after commencing therapy there was improvement or marked improvement of pain in significantly more patients in the calcitonin group (5/13) than in the placebo group (0/12) (Fisher's exact two-tailed probability test, P = 0.0484).
3 context sentences(design, population, supporting numbers)
Thirty-two patients with established malignancy and associated pain participated in a randomised double-blind controlled trial.
They received salmon calcitonin SC 200 UI or matching placebo 6-hourly for 48 h and were assessed by using a combination of a 20-point visual analogue scale (VAS), a 4-point physician's global pain scale, and ranking of the co-administered analgesics into 20 grades of potency.
Twenty-five patients (13 calcitonin, 12 placebo) were evaluated.